Interferon-alpha2a and Vogt-Koyanagi-Harada disease: a double-edged sword?
- PMID: 17318324
- DOI: 10.1007/s10792-007-9040-2
Interferon-alpha2a and Vogt-Koyanagi-Harada disease: a double-edged sword?
Abstract
Successful therapy based on the use of interferon-alpha has been reported in different types of severe chronic uveitis. The immunomodulatory effects of this drug, combined with its antiviral properties seem to contribute to its efficacy in the treatment of different forms of severe and refractory uveitis such as Vogt-Koyanagi-Harada disease, Behçet-associated uveitis, or even human herpes virus 8 (HHV-8) associated uveitis. At the same time, severe ocular complications have been reported in patients treated with interferon-alpha for chronic viral hepatitis C. Among these complications, six cases of Vogt-Koyanagi-Harada-like disease have been described.We report a small case series of two patients with refractory Vogt-Koyanagi-Harada disease, treated with interferon-alpha and discuss the potential benefits or detrimental role of interferon therapy in these patients.
Similar articles
-
Vogt-Koyanagi-Harada disease occurring during interferon-alpha and ribavirin therapy for chronic hepatitis C virus infection.Int Ophthalmol. 2010 Oct;30(5):611-3. doi: 10.1007/s10792-010-9357-0. Epub 2010 Feb 23. Int Ophthalmol. 2010. PMID: 20177954
-
[Vogt-Koyanagi-Harada disease associated with interferon-alpha and ribavirin therapy for chronic hepatitis C infection].J Fr Ophtalmol. 2010 Mar;33(3):185-8. doi: 10.1016/j.jfo.2010.01.009. Epub 2010 Feb 20. J Fr Ophtalmol. 2010. PMID: 20172621 French.
-
Vogt-Koyanagi-Harada disease occurring during pegylated interferon-α2b and ribavirin combination therapy for chronic hepatitis C.Korean J Hepatol. 2011 Mar;17(1):61-5. doi: 10.3350/kjhep.2011.17.1.61. Korean J Hepatol. 2011. PMID: 21494079 Free PMC article.
-
Vogt-Koyanagi-Harada disease occurring during interferon alpha therapy for chronic hepatitis C.J Gastroenterol. 2004 Nov;39(11):1106-9. doi: 10.1007/s00535-004-1452-4. J Gastroenterol. 2004. PMID: 15580406 Review.
-
Induction of Vogt-Koyanagi-Harada Disease by Interferon-Alpha and Ribavirin Treatment in Patients with Hepatitis C: A Case Report and Review of the Literature.Ocul Immunol Inflamm. 2019;27(2):229-234. doi: 10.1080/09273948.2017.1373827. Epub 2017 Oct 12. Ocul Immunol Inflamm. 2019. PMID: 29023176 Review.
Cited by
-
Systemic glucocorticoid-free therapy with adalimumab plus immunosuppressants versus conventional therapy in treatment-naïve Vogt-Koyanagi-Harada disease patients.Ann Transl Med. 2022 Jun;10(12):699. doi: 10.21037/atm-22-2668. Ann Transl Med. 2022. PMID: 35845536 Free PMC article.
-
Ophthalmologic complications of antiviral therapy in hepatitis C treatment.World J Gastroenterol. 2013 Dec 7;19(45):8227-37. doi: 10.3748/wjg.v19.i45.8227. World J Gastroenterol. 2013. PMID: 24363513 Free PMC article. Review.
-
Vogt-Koyanagi-Harada disease occurring during interferon-alpha and ribavirin therapy for chronic hepatitis C virus infection.Int Ophthalmol. 2010 Oct;30(5):611-3. doi: 10.1007/s10792-010-9357-0. Epub 2010 Feb 23. Int Ophthalmol. 2010. PMID: 20177954
-
Anti-inflammatory treatment of uveitis with biologicals: new treatment options that reflect pathogenetic knowledge of the disease.Graefes Arch Clin Exp Ophthalmol. 2010 Nov;248(11):1531-51. doi: 10.1007/s00417-010-1485-8. Epub 2010 Aug 25. Graefes Arch Clin Exp Ophthalmol. 2010. PMID: 20737162 Review.
-
Reappraisal of the management of Vogt-Koyanagi-Harada disease: sunset glow fundus is no more a fatality.Int Ophthalmol. 2017 Dec;37(6):1383-1395. doi: 10.1007/s10792-016-0395-0. Epub 2016 Nov 14. Int Ophthalmol. 2017. PMID: 27844182 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources